Board of Directors

 

Alan Crane

Entrepreneur Partner, Polaris Partners Chairman & Co-Founder, Pandion Therapeutics

Nancy Stagliano, PhD

Independent Director

Don Frail, PhD

Independent Director

Jill Carroll

Principal, S.R. One

Mitchell Mutz, PhD

Senior Investment Director, Roche Venture Fund

Carlo Rizzuto, PhD

Partner, Versant Ventures

Rahul Kakkar, MD

Chief Executive Officer

Katie Ellias

Managing Director, JDRF T1D Fund, board observer

Alan Crane   Entrepreneur Partner, Polaris Partners Chairman & Co-Founder, Pandion Therapeutics

Alan Crane joined Polaris Partners in 2002 and serves as both a Partner and Entrepreneur focusing on building and investing in healthcare companies. He has served as founder and/or has played a significant role as chairman and CEO in building six Polaris companies including: Momenta Pharmaceuticals (NASDAQ: MNTA), Cerulean Pharma(NASDAQ:CERU), Visterra, Navitor Pharmaceuticals, XTuit Pharmaceuticals and Arsia Therapeutics (acquired by Eagle Pharmaceuticals). In addition, he currently serves on the board of Seventh Sense Biosystems and has previously represented Polaris on the boards of T2 Biosystems (NASDAQ: TTOO), Ocular Therapeutix (NASDAQ: OCUL), Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by Glaxo SmithKline) and Adnexus Therapeutics (acquired by Bristol Myers Squibb).

From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals (NASDAQ: MNTA). He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was Senior Vice President of Global Corporate Development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade® which became the main basis of the company’s $9B acquisition by Takeda. Before joining Millennium, Alan was a marketing executive at DuPont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.

Alan received the Ernst & Young’s Entrepreneur of the Year award for New England and is an Always-On Venture Capital 100 recipient. His current and former non-profit positions include: Selection Committee for the Harvard Life Lab, Expert-in-Residence at the Harvard School of Engineering, Board Member of the Boston Children’s Hospital Trust, Founder and Vice Chair of the Autism Consortium, and President of the Board of Gann Academy.

Alan earned a BA in Biology, summa cum laude, from Harvard College, an MA in Cellular and Developmental Biology from Harvard Graduate School of Arts & Sciences and an MBA, with honors, from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.

Alan enjoys spending his free time traveling with his wife and three sons and working with non-profits in education and healthcare.

Nancy Stagliano, PhD   Independent Director

Nancy Stagliano, Ph.D., is an accomplished serial biotechnology entrepreneur. As chief executive officer, Dr. Stagliano has successfully launched and/or exited three consecutive biotech companies: CytomX Therapeutics (CTMX), iPierian and, most recently, True North Therapeutics. As chief executive officer and co-founder of True North Therapeutics, Dr. Stagliano led the company to its recent acquisition by Bioverativ, Inc. for a total deal value of up to $825 million. Under her leadership, True North discovered and developed a first-in-class monoclonal antibody in the classical complement pathway TNT009, which received breakthrough therapy designation from the U.S. Food & Drug Administration for the orphan indication, Cold Agglutinin Disease.

Previously, Dr. Stagliano was chief executive officer of iPierian, Inc., which applied human iPSCs to model neurodegenerative diseases. The company and its lead antibody program against Tau for the treatment of progressive supranuclear palsy (PSP) and Alzheimer’s disease were acquired by Bristol-Myers Squibb in April of 2014 for a total deal value of $725 million; the antibody is currently in a Phase 2 trial in PSP led by Biogen. From 2008–2010, Dr. Stagliano was the chief executive officer and co-founder of CytomX Therapeutics and a lead inventor on the CytomX Probody platform. Before moving to California, Dr. Stagliano worked in Cambridge, Mass., where she had an eight-year tenure at Millennium Pharmaceuticals.

Dr. Stagliano received her bachelor of science degree in electrical engineering and master of science degree in biomedical engineering from Drexel University in Philadelphia. She obtained her doctor of philosophy degree in neuroscience from the University of Miami, Miller School of Medicine, in Miami.

Don Frail, PhD   Independent Director

Don Frail, PhD, is an accomplished drug hunter with more than 25 years of experience across therapeutic areas. He is current a Senior Vice President at Allergan, leading the R&D efforts across research, pre-clinical sciences, clinical pharmacology, and external science/partnering. Since joining Allergan in 2014, he has been involved in most internally developed and externally sourced programs. Prior to Allergan, he served in leadership positions at Astra-Zeneca, Pfizer, Pharmacia, Wyeth and Abbott Labs and has been involved in the entry of more than 25 compounds into development.

Jill Carroll   Principal, S.R. One

Ms. Jill Carroll is a Principal of SR One, and she joined SR One in 2011 with a background in biotech partnering and corporate development. Previously, she was Senior Director, Corporate Development at Dynavax Technologies (NASDAQ: DVAX) where she completed multiple pharma partnerships and substantial private and public financings. Jill was formerly a biopharmaceutical industry consultant at Clearview Projects and Mercer Management Consulting. She is a Director at Second Genome, Gotham Therapeutics, Arcellx, and Nkarta. She received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University.

Mitchell Mutz, PhD   Senior Investment Director, Roche Venture Fund

Mitchell Mutz, PhD, is Senior Investment Director at the Roche Venture Fund. He joined Roche in 2017, bringing a broad depth of experience as founder, President, and Chief Scientific Officer of Amplyx Pharmaceuticals, a clinical stage therapeutics company that is currently developing APX001, a novel, broad spectrum antifungal compound. Amplyx has attracted over $130M in venture and grant financing. At Amplyx, he identified, led negotiations, and successfully in-licensed APX001. Mitchell also authored or co-authored 13 funded NIH grant proposals, garnering over $11M in non-dilutive funding. He is also an inventor on 32 issued patents.

Previously, Mitchell was the first employee and Principal Scientist at Labcyte Inc., Sunnyvale, CA, a tools company that uses acoustic beams to achieve precise, non-contact transfer of liquid without the use of pipet tips. Labcyte has received widespread industry recognition including selection by the World Economic Forum as a 2015 Technology Pioneer, has over 220 employees worldwide, and has seen their technology adopted by all top ten large pharmaceutical companies and a host of smaller biotechnology companies, universities, and research institutes. Prior to Labcyte, he was a research scientist at Scios which was later acquired by Johnson and Johnson. Mitchell currently serves on the board of Purigen Biosytems, is a board observer for Biodesy and Fabric Genomics, and was previously on the board of Amplyx.

Dr. Mutz received his PhD in Chemistry from the University of Rochester, NY, his Diploma in Orchestral Studies from the University of London, England, and a BA in Chemistry from Oberlin College.

Carlo Rizzuto, PhD   Partner, Versant Ventures

Carlo Rizzuto is a Partner with Versant Ventures and focuses on biotech investing and company building.

Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising US and European clients in the pharmaceutical, payor and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup.

Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.

Rahul Kakkar, MD   Chief Executive Officer

Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience, spanning founding and building biotechnology companies, as well as working as a practicing physician. Most recently, he served as an executive at Corvidia Therapeutics where he was a founder, Chief Medical Officer and Chief Strategy Officer, guiding the company from seed stage through Series B and its lead asset through clinical proof of concept. Previously, he was Director for Emerging Innovations at AstraZeneca, responsible for preclinical through Phase 2 clinical studies both for compounds within the AstraZeneca pipeline and in support of compound out-licensing efforts. Dr. Kakkar has also served as an advisor to life sciences venture firms. He continues to practice medicine as Associate Physician at Brigham and Woman’s Hospital and is a Lecturer in Medicine at Harvard Medical School. Dr. Kakkar is dual-trained via the American Board of Internal Medicine Fast Track program in molecular biology and clinical cardiology. He received his BA from Tufts University and MD from the Tufts School of Medicine where he was a junior inductee of the Alpha Omega Alpha society. He is a fellow of the American College of Cardiology.

Katie Ellias   Managing Director, JDRF T1D Fund, board observer

Katie Ellias joined the T1D Fund in July 2018 as a Managing Director from Endeavour Vision, a Geneva-based growth stage venture fund, where she focused on medical devices and digital health as Senior Investment Director. She was previously Principal at Sofinnova Partners, Paris, a leading early stage life sciences fund, investing in medical technologies. She served as Board Observer for ReCor Medical (sold to Otsuka Holdings), CorWave, Shockwave Medical (NASDAQ: SWAV), RefleXion Medical, Pixium Vision (PIX.PA), and MD Start, a medical device accelerator.

Prior to VC, Katie held roles in Business Development, Sales and Marketing at Medtronic in the Cardiac and Vascular businesses. She began her career at McKinsey & Company and Partners Healthcare in Boston. Katie holds a M.B.A. in Healthcare Management from the Wharton School at the University of Pennsylvania and a B.A. cum laude in International Relations and Political Science from Yale University.

 
Back to Top